CLAIMS:

- 1. A method for the treatment or prevention of Alzheimer's disease comprising administering to a subject in need thereof a therapeutically-effective amount of a compound which inhibits the formation or release of β -amyloid and a therapeutically-effective amount of a nitric oxide releaser.
 - 2. The method according to claim 1 wherein the nitric oxide releaser is a nitrate ester of an alkanol.

10

5

- 3. The method according to claim 1 wherein said inhibitor and said nitric oxide releaser are combined in a single dosage formulation.
- 4. The method according to claim 3 wherein said inhibitor and said nitric oxide releaser are combined in a compound of formula I:

Ι

where R is such that R-CH₂OH or R-CHO is an inhibitor of the formation or release of $A\beta$;

- or a pharmaceutically acceptable salt thereof.
 - 5. A compound suitable for use in the method of claim 1, said compound being of formula II:

$$Ar^{1}SO_{2}$$
 Ar^{2}
 CH_{2}
 R^{1c}
 CH_{2}
 R^{1b}
 O
 CH_{2}
 CH_{2}
 CH_{2}
 O
 O
 O

 \mathbf{II}

25

wherein:

m is 0 or 1;

n is 0 or 1;

p is an integer in the range 1-6;

L is a linking group;

5

25

R^{1b} represents H, C₁₋₄alkyl or OH;

R^{1c} represents H or C₁₋₄alkyl;

Ar¹ and Ar² independently represent phenyl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, CHF₂, OH, OCF₃, CHO, CH=NOH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, C₂₋₆acyl, C₂₋₆alkenyl and C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy;

- or a pharmaceutically acceptable salt thereof.
 - 6. A compound according to claim 5 wherein m is 1 and R^{1b} and R^{1c} are both H.
- 7. A compound according to claim 5 wherein Ar¹ is 4-chlorophenyl or 4-trifluoromethylphenyl and Ar² is 2,5-difluorophenyl.
 - 8. A compound according to claim 5 wherein L is represented by the formula:

20 -L¹-C(O)O-

wherein L^1 is a hydrocarbon residue of up to 10 carbon atoms, optionally bearing up to 3 substituents selected from halogen, CN, OH and C_{1-4} alkoxy.

9. A compound according to claim 8 wherein L¹ represents

-Ar-CH=CH-

wherein Ar is a phenyl group bearing up to 2 substituents selected from hydroxy and methoxy.

10. A compound according to claim 5 wherein L represents:

11. A compound according to claim 5 selected from:

5

and

and pharmaceutically acceptable salts thereof.

10

- 12. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.
- 13. A method of treatment of a subject suffering from or prone to
 15 Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to claim 5.

14. A method of preparing a compound according to claim 5 comprising reaction of a compound of formula III with silver nitrate:

$$Ar^{1}SO_{2}$$
 Ar^{2}
 R^{1c}
 R^{1c}
 R^{1b}
 R^{1b}
 R^{1b}
 R^{1b}
 R^{1b}
 R^{1b}
 R^{1b}
 R^{1b}
 R^{1b}

where X represents chlorine, bromine or iodine, and m, n, p, L, R^{1b}, R^{1c}, Ar¹ and Ar² are as defined in claim 5.

5